Administrative Claims Analysis of New Exenatide Patients with Type 2 Diabetes

Wade, Ron; Quimbo, Ralph; Barron, John; Schroeder, Brock; Wintle, Matthew; Misurski, Derek; Oglesby, Alan
June 2007
Diabetes;Jun2007 Supplement 1, Vol. 56, pA561
Academic Journal
Traditional antidiabetic therapies often fail to maintain glycemic control over time. In this retrospective analysis using a large, national commercial health care claims database, we describe baseline characteristics, comorbidities, and concomitant therapies in patients prescribed exenatide in the first 13 months following FDA approval. A total of 3578 patients were identified who had a prescription claim for exenatide between May 1, 2005 and May 31,2006, ≥12 months of pre-index eligibility (first claim defined as index date), and were ≥18 years old. Of these, 3454 patients (96.5%) had a pre-index diagnosis for type 2 diabetes based on diagnosis code and/or meditation use. Mean (±SD) age was 54.24±10.0 years; 49.7% were female and 12.7% were ≥65 years of age. Baseline A1C values obtained within 100 days before the index date were available for 340 patients (mean±SD = 8.04±1.6%). The most common comorbidities associated with diabetes reported in the 12 months prior to the index date were dyslipidemia (87.7%), hypertension (64.3%), other cardiovascular disease (27.7%), and obesity (17.7%). Most patients analyzed (94.2%) were treated with at least one other antidiabetic medication at baseline; 22.1% with one drug, 34.3% with 2 drugs, and 37.8% with ≥3 drugs. Metformin was the most common baseline therapy (74.5%), followed by thiazolidinediones (50.6%), sulfonylureas (49.0%), and insulin (29.7%). This study provides the first nonclinical trial population analysis of the baseline A1C, demographics, comorbidities, and concomitant diabetes therapies in patients initiated on exenatide. The mean baseline A1C indicates that these patients were not achieving glycemic control as defined by current guidelines, supporting the notion that diabetes remains a difficult disease in which to achieve therapeutic goals. In the first 13 months since FDA approval, exenatide was predominantly prescribed to patients with type 2 diabetes who were failing to achieve glycemic control with prior antidiabetic therapy.


Related Articles

  • 10. Glucose control: Insulin-based therapies.  // Journal of Endocrinology, Metabolism & Diabetes of South Africa;Jun2012, Vol. 17 Issue 2, pS32 

    The article discusses the use of insulin in treating patients with type 2 diabetes. It cites several studies that provide guidance for the rational use of various insulins in diabetes treatment, and offers recommendations for the initiation of basal insulin and pre-mixed insulin in diabetic...

  • Treatment Effects on Measures of Body Composition in the TODAY Clinical Trial. El ghormli, Laure // Diabetes Care;Jun2013, Vol. 36 Issue 6, p1742 

    OBJECTIVE--The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial showed superiority of metformin plus rosiglitazone (M+R) over metformin alone (M), with metformin plus lifestyle (M+L) intermediate in maintaining glycemic control. We report here treatment effects on...

  • Dapagliflozin maintains HR-QOL in diabetes.  // PharmacoEconomics & Outcomes News;10/27/2012, Issue 665, p10 

    The article reports on an international, double-blind clinical trial on the impact of dapagliflozin in health-related quality of life (HR-QOL) of patients with type 2 diabetes.

  • New oral therapies for type 2 diabetes. Purnell, Jonathan Q.; Hirsch, Irl B. // American Family Physician;11/1/1997, Vol. 56 Issue 7, p1835 

    Provides information on several oral agents for the treatment of type two diabetes available in the United States. Side effects of metformin, acarbose, troglitazone; Its mechanism of action of the drugs; Adverse effects of the drugs.

  • The extracts of Berberis lycium and diabetes mellitus in alloxan monohydrate induced diabetic rats. Mustafa, Khalid Ghazanfar; Ganai, Bashir Ahmad; Akbar, Seema; Dar, Mohammad Younis; Tantry, Mudasir Ahmad; Masood, Akbar // Journal of Pharmacy Research;Aug2011, Vol. 4 Issue 8, p2570 

    Incidence of type II diabetes is rapidly increasing worldwide. In order to identify complementary or alternative approaches to existing medications, we studied antidiabetic properties of Berberis lycium-a natural health product recommended for diabetes treatment in kashmir. The hypoglycemic...

  • American Diabetes Association.  // BioWorld Today;6/9/2009, Vol. 20 Issue 109, p9 

    The article deals with the results presented by Intarcia Therapeutics from a Phase Ib study which examined the effectiveness of ITCA 650 in treating Type II diabetes. Results showed significant reductions in fasting plasma glucose levels within 24 hours of the start of treatment, as well as a...

  • UPDATE ON TREATMENT OF TYPE 2 DIABETES MELLITUS. RUNGBY, JORGEN // Problemy Endokrinologii;2017 Supplement, p6 

    Type 2 diabetes is a heterogeneous disease and therefore it may be complicated to treat hyperglycaemia. Treatment is ideally based on pathophysiological knowledge about the causes of hyperglycaemia in the individual patient: «The right pill in the right mouth». The lecture will focus on...

  • Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It's Time to Move On! Genuth, Saul // Diabetes Care;Jan2015, Vol. 38 Issue 1, p170 

    The article discusses the research supporting the discontinuations of using sulfonylureas (SU) as a first-line add on to metformin in treating type 2 diabetes. Topics include the joint recommendations of the American Diabetes Association (ADA) and the European Association for the Study of...

  • Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus. Chamarthi, Bindu; Gaziano, J. Michael; Blonde, Lawrence; Vinik, Aaron; Scranton, Richard E.; Ezrokhi, Michael; Rutty, Dean; Cincotta, Anthony H. // Journal of Diabetes Research;4/28/2015, Vol. 2015, p1 

    Background. Type 2 diabetes (T2DM) patients, including those in good glycemic control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control may reduce long-term CVD risk. However, other risk factors such as elevated vascular sympathetic tone and/or...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics